Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: GM-611; Mitemcinal-Fumarate

Latest Information Update: 22 Jan 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Biopharmaceuticals; Chugai Pharmaceutical
  • Class Antibacterials; Gastrokinetics; Irritable bowel syndrome therapies; Macrolides
  • Mechanism of Action Motilin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic gastroparesis; Gastro-oesophageal reflux; Gastroparesis; Irritable bowel syndrome

Most Recent Events

  • 28 Oct 2005 Chugai is preparing to commence phase III studies in the US with GM 611 for the treatment of diabetic gastroparesis
  • 08 Jun 2005 Data presented at the Digestive Disease Week conference (DDW-2005) have been added to the Digestive disorders therapeutic trials section
  • 22 Apr 2005 No development reported - Phase-II for Gastro-oesophageal reflux in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top